Analysis Tools|
Allele Symbol Allele Name Allele ID |
Insm1tm1.1(GFP/cre)Mgn targeted mutation 1.1, Mark A Magnuson MGI:5576020 |
||||||||||||
| Summary |
2 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• die between E15.5 and E18.5, with about 10% surviving to E18.5
|
|
• only 8% of GFPCre-expressing endocrine cells are insulin positive at E18.5 and there is a decrease in cells expressing glucagon (from 24% to 11%), somatostatin (from 11% to 7%) and ghrelin (from 8% to 5%), indicating a possible defect in hormone production
• number of pancreatic polypeptide-positive cells is increased from 7% to 12% at E18.5
|
|
• size of the endocrine progenitor cells is increased at E18.5 and their shape becomes irregular
• endocrine progenitor cells are less differentiated
|
|
• endocrine cells remain closely associated with pancreatic ductal cells, indicating a defect of differentiating pre-endocrine cells to migrate away from pancreatic ductal regions
|
|
• endocrine progenitor cells show a slight decrease in proliferation (from 1.4% to 0.9%) at E15.5 and up to a 7-fold decrease at E18.5
|
|
• endocrine progenitor cells show a slight decrease in proliferation (from 1.4% to 0.9%) at E15.5 and up to a 7-fold decrease at E18.5
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 10/29/2024 MGI 6.24 |
|
|
|
||
